The Kerala government has formed an expert panel to investigate claims that expired Remdesivir was given to Nipah patients at Kozhikode Medical College. The probe examines 3,000 vials procured in 2021 that allegedly expired in 2023. This investigation raises concerns regarding public medical supply chain transparency and the governance of state healthcare procurement agencies.
The Kerala state government has launched a formal inquiry into medical procedures at Kozhikode Medical College following serious allegations that expired antiviral medication was administered to patients. The Health Minister, K. Muraleedharan, confirmed that an expert committee led by Dr. Aravind is now investigating the usage of Remdesivir doses that were reportedly past their shelf life.
The probe specifically focuses on a stock of 3,000 vials procured back in 2021. According to official records, these supplies reached their expiry date in May 2023, yet reports suggest they may have remained in the hospital system well beyond that window. Investigators are cross-referencing patient treatment logs against specific batch numbers to determine exactly when the medicine was used and how the potential oversight occurred.
Beyond the expiry issue, the investigation is scrutinizing significant packaging irregularities. Hospital authorities flagged that some of the contested medication lacked manufacturing dates entirely and only displayed expiry information. There are also claims that certain supplies were labeled for clinical trial use, which would violate standard protocols for distributing medicines in public health settings. These findings have prompted a wider review of the procurement processes managed by the Kerala Medical Services Corporation Limited.
The government is also reviewing the history of the 2021 procurement under the Karunya scheme. This includes auditing the role of foreign pharmaceutical intermediaries involved in the supply chain, particularly regarding emergency stocks that were reportedly sourced from Bahrain. The audit aims to identify whether unauthorized agents played a role in the transaction and if the distribution of these drugs was handled according to safety norms.
For the healthcare sector and public administration, this event highlights the importance of rigorous inventory management. The integrity of the drug supply chain is essential not only for patient safety but also for maintaining trust in government-run medical institutions. The findings of the expert committee will likely serve as a basis for evaluating potential systemic failures in how the state monitors, stores, and uses essential medical stocks.
Investors and stakeholders in the healthcare space may track the outcome of this probe, as it may lead to stricter regulatory oversight, mandatory supply chain audits, and changes in how state agencies handle medical procurement. The final report is expected to clarify whether the alleged lapses had a direct impact on patient health and will likely influence future procurement guidelines and vendor accountability protocols in the region.